TCTR20131019001招募中未知
Clinical trial in assigning of tacrolimus dosage regimen according to CYP3A5 genotype in kidney transplant recipients
The National Science and Technology Development Agency0 个研究点目标入组 140 人开始时间: 2013年10月19日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 60 Years（—）
- 性别
- All
入选标准
- •Kidney transplantation recipients who
- •1.Age > 18 year old
- •2.Will have kidney transplantation at Srinagarind hospital, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
- •3.Will have the first kidney transplantation
- •4.Will receive tacrolimus as immunosuppressive to prevent graft rejection
- •5.Will have AST and ALT < 2 time of normal level, total bilirubin <1.5 mg/dl and direct bilirubin within normal limited
- •6.Welling to volunteer in this study and sign the inform consent
排除标准
- •Kidney transplantation recipients who
- •1.Refuse to join this study
- •2.Have drug allergy to tacrolimus
- •3.Have Pregnancy and lactating
研究者
相似试验
已完成
1 期
Clinical trial to examine the effective dose and the safety of [11C]K-2 synthesized by dedicated machine in healthy male volunteersHealthy volunteersJPRN-UMIN000026357Yokohama City University12
进行中（未招募）
不适用
Clinical trial to assess the pharmacokinetic/Pharmacodynamic characteristics and safety/tolerability of CKD-519 new formulation in healthy male subjectsEndocrine, nutritional and metabolic diseaseKCT0001729Chong Kun Dang30
已完成
不适用
Single dosing clinical trial to assess the pharmacokinetic characteristics and safety/tolerability of HL151 formulation in healthy male subjectsKCT0002201Hanlim Pharmaceutical30
已完成
不适用
Repeated dosing clinical trial to assess the pharmacokinetic characteristics and safety/tolerability of HL151 formulation in healthy male subjectsKCT0002200Hanlim Pharmaceutical30
进行中（未招募）
不适用
The Pharmacokinetic Study of the Fixed-dose Combination of Micronized Fenofibrate and Pitavastatin CaDiseases of the circulatory systemKCT0001258Hanlim Pharmaceutical40